Developing Therapeutics That Teach the Body to Heal Itself
EVENT AGT™ Celebration Of First Safety Data In The HIV Cure Human Trial View Press Release About the Event On July 29th, 2021, we celebrated amazing news regarding our human trial of our HIV Cure Program. The Data and Safety Monitoring Board (DSMB) voted unanimously to continue AGT's HIV Cure Program without modification after safety... [Read More]
AGT hereby invites you to participate in an investor-only information session via Zoom. There are two dates to choose from, or you may attend both. CEO Jeff Galvin and CSO David Pauza, Ph.D., will give an update on the company’s execution this year and the next chapter of AGT’s strategy. The presentation will include a review of the IND approval and clinical plans for AGT103-T. The meeting will be held on two separate dates to accommodate all investors. This webinar is only for existing investors.
In this webinar, Jeff Galvin will share his journey from executive positions and entrepreneurial ventures in Silicon Valley to founding and leading a ground-breaking Gene and Cell Therapy company. Reflecting on the last technology revolution sets the stage for what Galvin will do to maximize the power of gene and cell therapy to reduce suffering and mortality from serious human diseases: apply the lessons he learned in the last technology revolution of computers to the technical revolution of the next 100 years of genetic medicines in the “human-computer.”
